Patisiran prevents functional decline in patients with cardiac amyloidosis
1. In this randomized controlled trial, patisiran demonstrated a reduction in functional capacity decline transthyretin amyloidosis (ATTR amyloidosis) with a ...
Tag: transthyretin amyloidosis
#VisualAbstract: Patisiran Treatment in Patients with Transthyretin Cardiac Amyloidosis
Click here to read this study in NEJM. ©2023 2 Minute Medicine, Inc. All rights reserved. No works may be ...